MG
OACC

Michael Gelband’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Michael Gelband’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-293,153
Closed -$3M – 2073
2025
Q1 		$3M Sell
293,153
-6,847
-2% -$68.7K 0.03% 562
2024
Q4 		$2.99M Buy
+300,000
New +$2.99M 0.02% 583

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
LIP
Lighthouse Investment Partners Palm Beach Gardens, Florida $3.66B AUM 32.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Michael Gelband's OACC Position: Q2 2025 in Review

Michael Gelband sold out of Oaktree Acquisition Corp III Life Sciences (OACC) in Q2 2025, closing a stake of 293,153 shares — an estimated $3M sold.

Michael Gelband first reported a position in OACC in Q4 2024 and held it in 2 quarters. The position peaked at $3M in Q1 2025. 47 funds tracked by Wall St. Rank hold OACC as of Q2 2025.

  • Michael Gelband reported no remaining Oaktree Acquisition Corp III Life Sciences position as of Q2 2025 after selling out during the quarter.
  • Michael Gelband sold 293,153 Oaktree Acquisition Corp III Life Sciences shares in Q2 2025, an estimated $3M.
  • Michael Gelband first reported a position in Oaktree Acquisition Corp III Life Sciences in Q4 2024 and held it in 2 quarters.
  • Michael Gelband's Oaktree Acquisition Corp III Life Sciences position peaked at $3M in Q1 2025.
  • 47 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.